Järfälla, Sweden

Christopher Graae

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: St. Jude Medical Ab. Active years: 2014.


% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christopher Graae: Innovator in Medical Device Technology

Introduction

Christopher Graae is a notable inventor based in Järfälla, Sweden. He has made significant contributions to the field of medical technology, particularly through his innovative patent related to implantable medical devices.

Latest Patents

Graae holds a patent for a "Method and implantable medical device (IMD) for monitoring permeability status of cell membranes." This device includes a signal generator that produces a current signal with a frequency slightly less than the β-dispersion frequency of tissue. The device applies this signal over the tissue, while a signal measurer captures the resulting voltage signal. An impedance parameter is then calculated from the applied and measured signals by a parameter determiner. The status monitor uses this impedance parameter to assess the permeability status of cell membranes in the tissue.

Career Highlights

Christopher Graae is associated with St. Jude Medical AB, where he has been instrumental in advancing medical device technology. His work focuses on improving the monitoring of cell membrane permeability, which is crucial for various medical applications.

Collaborations

Graae has collaborated with notable colleagues, including Andreas Blomqvist and Jörgen Edvinsson, contributing to the development of innovative medical solutions.

Conclusion

Christopher Graae's contributions to medical device technology through his patent demonstrate his commitment to advancing healthcare solutions. His work continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…